[go: up one dir, main page]

WO2026013162A1 - Vecteur vaccinal du virus herpès du dindon pour le traitement et la prévention d'infections provoquées par le virus de la grippe aviaire chez des dindons - Google Patents

Vecteur vaccinal du virus herpès du dindon pour le traitement et la prévention d'infections provoquées par le virus de la grippe aviaire chez des dindons

Info

Publication number
WO2026013162A1
WO2026013162A1 PCT/EP2025/069655 EP2025069655W WO2026013162A1 WO 2026013162 A1 WO2026013162 A1 WO 2026013162A1 EP 2025069655 W EP2025069655 W EP 2025069655W WO 2026013162 A1 WO2026013162 A1 WO 2026013162A1
Authority
WO
WIPO (PCT)
Prior art keywords
h5ha
cobra
sequence
rhvt
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2025/069655
Other languages
English (en)
Inventor
Francesco PRANDINI
Francesco Bonfante
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Vetmedica GmbH
Boehringer Ingelheim Animal Health Italy SpA
Original Assignee
Boehringer Ingelheim Vetmedica GmbH
Boehringer Ingelheim Animal Health Italy SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica GmbH, Boehringer Ingelheim Animal Health Italy SpA filed Critical Boehringer Ingelheim Vetmedica GmbH
Publication of WO2026013162A1 publication Critical patent/WO2026013162A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne une méthode de traitement ou de prévention d'infections provoquées par le virus de la grippe aviaire chez des dindons, consistant à administrer une quantité efficace d'un virus recombinant HVT-H5HA de type COBRA.
PCT/EP2025/069655 2024-07-10 2025-07-10 Vecteur vaccinal du virus herpès du dindon pour le traitement et la prévention d'infections provoquées par le virus de la grippe aviaire chez des dindons Pending WO2026013162A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP24187791 2024-07-10
EP24187791.9 2024-07-10
EP24220116 2024-12-16
EP24220116.8 2024-12-16

Publications (1)

Publication Number Publication Date
WO2026013162A1 true WO2026013162A1 (fr) 2026-01-15

Family

ID=96429733

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2025/069655 Pending WO2026013162A1 (fr) 2024-07-10 2025-07-10 Vecteur vaccinal du virus herpès du dindon pour le traitement et la prévention d'infections provoquées par le virus de la grippe aviaire chez des dindons

Country Status (1)

Country Link
WO (1) WO2026013162A1 (fr)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5122458A (en) 1984-08-24 1992-06-16 The Upjohn Company Use of a bgh gdna polyadenylation signal in expression of non-bgh polypeptides in higher eukaryotic cells
US5965138A (en) 1985-09-06 1999-10-12 Syntro Corporation Recombinant chimeric virus and uses thereof
US5980906A (en) 1994-12-30 1999-11-09 Rhone Merieux Live recombinant avian vaccine using an avian herpesvirus as vector
WO2008052173A2 (fr) 2006-10-27 2008-05-02 Boehringer Ingelheim Vetmedica, Inc. Nouvellles protéines h5, molécules d'acide nucléique, leurs vecteurs codants et leur utilisation médicale
WO2010010107A1 (fr) 2008-07-23 2010-01-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Nouveaux éléments régulateurs
WO2013024113A1 (fr) 2011-08-15 2013-02-21 Boehringer Ingelheim Vetmedica S.A. De C.V. Vaccins contre le virus grippal h5
WO2018112051A1 (fr) 2016-12-14 2018-06-21 Merial, Inc. Vecteurs hvt recombinants exprimant de multiples antigènes de pathogènes aviaires, et vaccins les contenant
WO2021257706A1 (fr) 2020-06-17 2021-12-23 Boehringer Ingelheim Animal Health USA Inc. Vecteurs hvt recombinants exprimant l'hémagglutinine de la grippe et compositions immunogènes, et leur fabrication et leurs utilisations

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5122458A (en) 1984-08-24 1992-06-16 The Upjohn Company Use of a bgh gdna polyadenylation signal in expression of non-bgh polypeptides in higher eukaryotic cells
US5965138A (en) 1985-09-06 1999-10-12 Syntro Corporation Recombinant chimeric virus and uses thereof
US5980906A (en) 1994-12-30 1999-11-09 Rhone Merieux Live recombinant avian vaccine using an avian herpesvirus as vector
WO2008052173A2 (fr) 2006-10-27 2008-05-02 Boehringer Ingelheim Vetmedica, Inc. Nouvellles protéines h5, molécules d'acide nucléique, leurs vecteurs codants et leur utilisation médicale
WO2010010107A1 (fr) 2008-07-23 2010-01-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Nouveaux éléments régulateurs
WO2013024113A1 (fr) 2011-08-15 2013-02-21 Boehringer Ingelheim Vetmedica S.A. De C.V. Vaccins contre le virus grippal h5
WO2018112051A1 (fr) 2016-12-14 2018-06-21 Merial, Inc. Vecteurs hvt recombinants exprimant de multiples antigènes de pathogènes aviaires, et vaccins les contenant
WO2021257706A1 (fr) 2020-06-17 2021-12-23 Boehringer Ingelheim Animal Health USA Inc. Vecteurs hvt recombinants exprimant l'hémagglutinine de la grippe et compositions immunogènes, et leur fabrication et leurs utilisations

Non-Patent Citations (35)

* Cited by examiner, † Cited by third party
Title
"Biocomputing: Informatics and Genome Projects", 1993, ACADEMIC PRESS
"Computer Analysis of Sequence Data, Part I", 1994, HUMANA PRESS
"GenBank", Database accession no. L06816.1
"Sequence Analysis in Molecular Biology", 1987, ACADEMIC PRESS
"Sequence Analysis Primer, Gribskov", 1991, M. STOCKTON PRESS
ADEDEJI ET AL., VETERINARY WORLD, 2017
ALFONSO ET AL., JOURNAL OF VIROLOGY, vol. 75, no. 2, 2001, pages 971 - 978
ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 10
ALTSCHUL ET AL., NUCLEIC ACIDS RES, vol. 25, no. 17, 1997, pages 3389 - 3402
ALTSCHUL, S. F. ET AL., J. MOLEC. BIOL., vol. 215, 1990, pages 403 - 410
BERTRAN KATERI ET AL: "Maternal antibody inhibition of recombinant Newcastle disease virus vectored vaccine in a primary or booster avian influenza vaccination program of broiler chickens", VACCINE, ELSEVIER, AMSTERDAM, NL, vol. 36, no. 43, 18 September 2018 (2018-09-18), pages 6361 - 6372, XP085496935, ISSN: 0264-410X, DOI: 10.1016/J.VACCINE.2018.09.015 *
BROWN ET AL., JOURNAL OF VETERINARY DIAGNOSTIC INVESTIGATION, vol. 21, 2009, pages 437 - 45
CARILLO, H.LIPMAN, D., SIAM J. APPLIED MATH., vol. 48, 1988, pages 1073
CORTES ET AL., AVIAN DISEASES, vol. 55, no. 2, 2011, pages 302 - 310
CRIADO ET AL., VACCINE, vol. 41, 2023, pages 2893 - 2904
CRIADO MIRIA F. ET AL: "Efficacy of multivalent recombinant herpesvirus of turkey vaccines against high pathogenicity avian influenza, infectious bursal disease, and Newcastle disease viruses", VACCINE, vol. 41, no. 18, 1 May 2023 (2023-05-01), AMSTERDAM, NL, pages 2893 - 2904, XP093138543, ISSN: 0264-410X, DOI: 10.1016/j.vaccine.2023.03.055 *
DAVISON, VETERINARY MICROBIOLOGY, vol. 86, no. 1, 2002, pages 69 - 88
DEVEREUX, J. ET AL., NUCLEIC ACIDS RESEARCH, vol. 12, no. 1, 1984, pages 387
DORSCH-HASLER ET AL., PNAS, vol. 82, 1985, pages 8325
KIM ET AL., JOURNAL OF VIROLOGY, vol. 81, no. 22, 2007, pages 12641 - 12653
KOEDOOD ET AL., J. OF VIROL., vol. 69, 1995, pages 2194 - 2207
LIN ET AL., J VET MED SCI., vol. 70, no. 11, 2008, pages 1147 - 52
MICHELJACKWOOD, ARCH VIROL, vol. 162, no. 12, 2017, pages 3661 - 3670
NAGUIB ET AL., TRANSBOUNDARY AND EMERGING DISEASES, vol. 69, 2021, pages 849 - 863
NEEDLEMANWUNSCH, J. MOL. BIOL., no. 48, 1970, pages 444 - 453
RAUW ET AL., AVIAN DIS, vol. 56, 2012, pages 913 - 22
RICKS ET AL., ADVANCES IN VET. MED., 1999, pages 495 - 515
SHARMA, AM. J. VET. RES., vol. 45, 1984, pages 1619 - 1623
SIJMONS ET AL., VIRUSES, no. 6, 2014, pages 1049 - 1072
SPACKMAN ET AL., J CLIN MICROBIOL, vol. 40, no. 9, 2002, pages 3256 - 60
THAI ET AL., AVIAN PATHOL, vol. 50, 2021, pages 174 - 181
TIRUMURUGAAN ET AL., PLOS ONE, vol. 6, no. 12, 2011, pages 28414
TOMAS ET AL., TRANSBOUND. EMERG. DIS., vol. 67, 2020, pages 1198 - 1212
WITTER ET AL., AM. J. VET. RES., vol. 31, 1970, pages 525
ZELNIK, V.: "Marek's Disease an Evolving Problem", 2004, ELSEVIER LTD, article "Diagnosis of Marek's disease"

Similar Documents

Publication Publication Date Title
JP5508252B2 (ja) 鳥インフルエンザ遺伝子を含有する組み換え七面鳥ヘルペスウイルス
US11512115B2 (en) Modified S1 subunit of the coronavirus spike protein
US11744888B2 (en) Method of treating or preventing clinical signs caused by infectious bronchitis virus with 4/91 IBV vaccine having heterologous spike protein
WO2017216180A1 (fr) Vaccin contre le virus de la bronchite infectieuse
US11696947B2 (en) H52 IBV vaccine with heterologous spike protein
EP2992005B1 (fr) Protéine de spicule mutante étendant le tropisme tissulaire du virus de la bronchite infectieuse (ibv)
JP4691495B2 (ja) コロナウイルススパイクｓ１融合蛋白及びその発現ベクター
JP2022515172A (ja) 複数の外来遺伝子を含む組換えトリヘルペスウイルス
CN111154778B (zh) 禽新城疫病毒新型基因工程亚单位疫苗
JP4474164B2 (ja) ワクチン製造のための連続継代性細胞系
WO2025044922A2 (fr) Vaccins vectorisés à dev contre la grippe aviaire h9
US20220213148A1 (en) Modified s2 subunit of the coronavirus spike protein
WO2026013162A1 (fr) Vecteur vaccinal du virus herpès du dindon pour le traitement et la prévention d'infections provoquées par le virus de la grippe aviaire chez des dindons
CN112111467B (zh) 一种基因vii型新城疫标记疫苗株及其制备方法与应用
WO2026013161A1 (fr) Vaccination de première immunisation et de rappel pour le traitement et la prévention d'infections provoquées par le virus de la grippe aviaire chez les aviens
US20030049825A1 (en) Nervous necrosis virus protein
CN114369580A (zh) 重组hvt及其用途
WO2025044920A2 (fr) Nouveaux vecteurs du virus de l'entérite du canard pour vaccins aviaires
WO2025044919A2 (fr) Nouveaux vecteurs du virus de l'entérite du canard
RU2850187C1 (ru) РЕКОМБИНАНТНЫЙ ГЕРПЕСВИРУС ИНДЕЕК (rHVT), СОДЕРЖАЩАЯ ЕГО ВАКЦИНА И ЕГО ПРИМЕНЕНИЕ
WO2025027551A2 (fr) Vaccin anti-ibv avec protéine de spicule de dmv/1639 hétérologue
CN102145166B (zh) 重组禽流感M2e的鸡传染性法氏囊VP2亚单位疫苗、其构建方法及其应用
EP0949333A1 (fr) Antigenes mutants du virus de la rougeole et genes les codant
BRPI0809529B1 (pt) Herpesvírus de peru vetorizado recombinante compreendendo um gene da hemaglutinina do vírus influenza aviário e vacina para aves